首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 再生醫學 > 幹細胞市場
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

幹細胞市場

Stem Cell Markets

出版商 Trimark Publications
出版日期 2010年06月 商品編碼 120863
內容資訊 英文 266 Pages
價格
US $ 3400 PDF by E-mail (Single User License)
US $ 6800 PDF By E-mail (Unlimited User License)


幹細胞市場 是由出版商Trimark Publications在2010年06月所出版的。 這份英文市場調查報告書包含266 Pages 價格從美金3400起跳。

簡介

本報告為，針對以幹細胞研發為目的之醫療研究領域市場區隔做相關解說，並進行目前一般幹細胞進程/使用中所採用之分析方式回顧以及疾病新療法開發中利用幹細胞之調查，以下列摘要形式闡述。

封面圖片：
表紙

第1章 概要

第2章 幹細胞生物學

  • 本章節範圍
  • 幹細胞基本特性
  • 幹細胞分類、幹細胞譜系及誘導
  • 幹細胞譜系
  • 幹細胞誘導
  • 幹細胞來源
  • 幹細胞分化
  • 幹細胞自我更新
  • 幹細胞反分化
  • 幹細胞之細胞核再設定

第3章 幹細胞治療

  • 本章節範圍
  • 病患及臨床之未滿足需求：幹細胞治療市場主要成長因素
  • 提供主要醫療區隔讓進入幹細胞市場較為簡單
  • 開發中幹細胞製品
  • 全球市場之幹細胞及相關製品
  • 全球市場中其他相關製品之重要性

第4章 幹細胞領域市場分析

  • 本章節範圍
  • 使用中幹細胞來源之市場區隔
  • 臍帶血幹細胞
  • 細胞培養產品
  • 細胞治療市場
  • 幹細胞領域中產業合作
  • 幹細胞產業中業務性成功之增加
  • 系統工程轉換至再生醫療
  • 細胞治療商業發展課題
  • 幹細胞企業及大型製藥公司之合作

第5章 細胞治療產業之策略路徑圖

  • 本章節範圍
  • 幹細胞產品營運生產之選項
  • 細胞治療產業之主要規定
  • 自家細胞治療產品之生產
  • 委託生產
  • 提供細胞治療所需之有效臨床計畫
  • 幹細胞治療區隔之商業模式
  • 目前細胞自我治療模式
  • 目前異體細胞療法
  • 價值鏈檢討及發展路徑
  • 幹細胞：研究室至市場

第6章 對再生醫療之財政援助

  • 本章節範圍
  • 對財政援助之激烈競爭壓力
  • 幹細胞研究、系統工程及再生醫療歷史
  • 政府對幹細胞研究支援之大綱

第7章 幹細胞研究現況

  • 本章節範圍
  • 北美幹細胞政策
  • 南美幹細胞政策
  • 歐洲幹細胞政策
  • 亞洲/大洋洲幹細胞政策
  • CIRM
  • CTDPH幹細胞研究計畫
  • TEDCO
  • MTTCF
  • NJCST
  • NYSTEM

第8章 企業簡介

附錄

圖表

目錄

Abstract

A stem cell is an extraordinary type of cell that has the ability to self-renew for long periods of time and to differentiate into specialized cells under appropriate physiological or experimental conditions. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. Recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders.

Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential.

The purpose of this TriMark Publications report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. It examines the use of stem cells in developing new therapies for disease.

Report Statistics

  • Publication Date: 01-JUN-10
  • Pages: 266
  • Format: PDF document

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 Scope of the Report
  • 1.3 Methodology
  • 1.4 Executive Summary
    • 1.4.1 Toxicity Screening for Drug Discovery and Development
    • 1.4.2 Autologous Cell Therapy
      • 1.4.2.1 Current Range of Applications for Autologous Cell Therapy (ACT)
      • 1.4.2.2 Commercially Available Autologous Treatments
      • 1.4.2.3 Autologous Treatment for Neurodegenerative Diseases
      • 1.4.2.4 Autologous Cell Therapy and Wound Healing
      • 1.4.2.5 Autologous Cell Therapy and Cosmetic Surgery
    • 1.4.3 Allogeneic Cell Therapy
      • 1.4.3.1 Allogeneic First Generation (Non-Stem Cell) Products
      • 1.4.3.2 Second Generation (Stem Cell-Based) Products
      • 1.4.3.3 Secondary Products
    • 1.4.4 Three Basic Types of Allogeneic Stem Cell Products
      • 1.4.4.1 Hematopoietic Stem Cells
      • 1.4.4.2 Neural Stem Cells
      • 1.4.4.3 Mesenchymal Stem Cells, Pancreatic Islet Stem Cells
  • 1.5 Current State of Stem Cell Market

2. Biology of Stem Cells

  • 2.1 Scope of this Chapter
  • 2.2 Basic Properties of Stem Cells
  • 2.3 Classification of Stem Cells, Stem Cell Lineages and their Derivation
    • 2.3.1 Embryonic Stem Cells
      • 2.3.1.1 Embryonic Germ Cells
      • 2.3.1.1 Fetal Stem Cells
      • 2.3.1.2 Umbilical Cord Stem Cells
    • 2.3.2 Adult Stem Cells
      • 2.3.2.1 Hematopoietic Stem Cells (Bone Marrow and Peripheral Blood)
      • 2.3.2.2 Mesenchymal Stem Cells (Bone Marrow Stroma)
      • 2.3.2.3 Gut Stem Cells
      • 2.3.2.4 Liver Stem Cells
      • 2.3.2.5 Bone and Cartilage Stem Cells
      • 2.3.2.6 Epidermal Stem Cells (Skin and Hair)
      • 2.3.2.7 Neuronal Stem Cells
      • 2.3.2.8 Pancreatic Stem Cells
      • 2.3.2.9 Eye Stem Cells
  • 2.4 Stem Cell Lineage
  • 2.5 Stem Cell Derivations
  • 2.6 Sources of Stem Cells
  • 2.7 Differentiation of Stem Cells
  • 2.8 Self-Renewal of Stem Cells
  • 2.9 Dedifferentiation of Cells
  • 2.10 Nuclear Reprogramming of Stem Cells

3. Stem Cell Therapy

  • 3.1 Scope of this Chapter
  • 3.2 Diseases with Unmet Clinical Need: Primary Driver of Stem Cell Therapy Market
  • 3.3 Leading Healthcare Segments Offering Scope for Easy Entry into Stem Cell Market
    • 3.3.1 Stem Cell Therapy in Orthopedics
      • 3.3.1.1 Stem Cells for the Repair of Tendons, Cartilages and Bone
    • 3.3.2 Stem Cell Therapy for Cardiac Diseases
    • 3.3.3 Stem Cell Therapy for Wound Healing
    • 3.3.4 Stem Cell Therapy for Diabetes
    • 3.3.5 Stem Cell Therapy for Neurodegenerative Diseases
      • 3.3.5.1 Clinical Activity for Cell Therapy into CNS
    • 3.3.6 Stem Cell Retinal Replacement Therapy
    • 3.3.7 Stem Cell Therapy for Liver Diseases
      • 3.3.7.1 Hepatocyte-like Cells for Liver Disease
      • 3.3.7.2 Cell Therapy for Liver Cirrhosis
    • 3.3.8 Cell Therapy for Peripheral Vascular Diseases
    • 3.3.9 Cell Therapy for Blood Disorders
    • 3.3.10 Biomaterials and Stem Cell Therapy
    • 3.3.11 Stem Cell Application in Drug Discovery
  • 3.4 Stem Cell Products in Development
  • 3.5 Stem Cell and Related Products in the Global Market
    • 3.5.1 Medtronic' s Infuse Bone Graft and the LT-Cage Device
    • 3.5.2 GenZyme' s Carticel®
    • 3.5.3 Stryker' s OP-1
    • 3.5.4 Osyris/Nuvasive' s Osteocel®
    • 3.5.5 RTI' s Spinal Implants
    • 3.5.6 Organogenesis™ Apligraft®
    • 3.5.7 Advanced Biohealing' s Dermagraft
    • 3.5.8 Integra' s Bilayer Matrix Wound Dressing
    • 3.5.9 LifeCell' s AlloDerm®
    • 3.5.10 Gytori' s Celution®
  • 3.6 Other Products of Importance in the Global Market
    • 3.6.1 Tissue-Engineered Wound Healing Products
      • 3.6.1.1 Oasis®
      • 3.6.1.2 Permacol™
      • 3.6.1.3 EZ-Derm®
      • 3.6.1.4 Matriderm®
      • 3.6.1.5 Alloderm®
      • 3.6.1.6 TransCyte®
      • 3.6.1.7 ICX-SKN®
      • 3.6.1.8 OrCel®
      • 3.6.1.9 Epicel®
      • 3.6.1.10 Myskin™
      • 3.6.1.11 EpiDex™
      • 3.6.1.12 Genzyme' s MACI® Implant
      • 3.6.1.13 Genzyme' s Epicel®
      • 3.6.1.14 ICX-TRC-Hair Regeneration Therapy
      • 3.6.1.15 VCT01™
    • 3.6.2 Cartilage Regeneration
      • 3.6.2.1 ChondroCelect/TGX001
      • 3.6.2.2 TGX002
      • 3.6.2.3 TGX003
      • 3.6.2.4 NOVOCART™
    • 3.6.3 BioTissue Technologies™ Products
      • 3.6.3.1 BioSeed®-S
      • 3.6.3.2 MelanoSeed
      • 3.6.3.3 Oral Mucosa BioSeed®-M
      • 3.6.3.4 BioSeed®-Oral Bone
      • 3.6.3.5 BioSeed®-C
    • 3.6.4 co.don®' s Autologous Cell Transplant Products
    • 3.6.5 Fidia Advanced Biopolymers™ Regenerative Medicine Products
      • 3.6.5.1 Hyalograft 3D™
      • 3.6.5.2 Laserskin®
      • 3.6.5.3 TISSUEtech autograft system™
      • 3.6.5.4 Hyalograft™ C
    • 3.6.6 Genzyme Biosurgery' s Tissue Engineering Products
      • 3.6.6.1 Carticel®
      • 3.6.6.2 Epicel®
    • 3.6.7 Interface Biotech AS™ Tissue Engineered Products
      • 3.6.7.1 Cartilink™ 1
      • 3.6.7.2 Cartilink™ 2
    • 3.6.8 Isotis S.A' s Tissue Engineered Products
      • 3.6.8.1 OsSatura™
      • 3.6.8.2 EpiDex
      • 3.6.8.3 AcuDress
    • 3.6.9 Karocell Tissue Engineering AB' s Tissue-Engineered Products
      • 3.6.9.1 Skin Cells
      • 3.6.9.2 Cartilage Cells
      • 3.6.9.3 Melanocytes
      • 3.6.9.4 Urothelial Tissue
    • 3.6.10 Smith & Nephew' s Tissue Engineering Products
      • 3.6.10.1 TransCyte
      • 3.6.10.2 Dermagraft
    • 3.6.11 Tetec Tissue Engineering Technologies AG' s Tissue Engineered Product
      • 3.6.11.1 Novacart®
    • 3.6.12 Verigen Transplantation Service International (VTSI)' s Tissue-Engineered Products
      • 3.6.12.1 CACI
      • 3.6.12.2 MACI®
      • 3.6.12.3 MACI® (A)
    • 3.6.13 XCELLentis™ Tissue-Engineered Products
      • 3.6.13.1 Ceal Platform
      • 3.6.13.2 LyphoDerm

4. Market Analysis of the Stem Cell Space

  • 4.1 Scope of this Chapter
    • 4.1.1 Various Market Segments in Stem Cell Space
    • 4.1.2 Market for Cell Therapy in the U.S.
  • 4.2 Market Segmentation by Source of Stem Cell Used
    • 4.2.1 Human Embryonic Stem Cells (hESCs) in Cell Therapy
      • 4.2.1.1 Investing Companies in hESCs
      • 4.2.1.2 Engineered Cartilage using hESCs
      • 4.2.1.3 Lung Tissue Differentiated from hESCs
      • 4.2.1.4 Human Mesenchymal Stem Cells (MSCs)
    • 4.2.2 Neural Stem Cells
    • 4.2.3 Human Hematopoietic Stem Cells
    • 4.2.4 Cord Blood Stem Cells
    • 4.2.5 Cancer Stem Cells
  • 4.3 Cord Blood Banking Market
    • 4.3.1 Cord Blood Stem Cell Applications
      • 4.3.1.1 Repairing Blood Vessels Using Cord Blood Stem Cells
      • 4.3.1.2 Cardiomyocetes and Cord Blood Stem Cells
      • 4.3.1.3 Congenital Heart Defects and Cord Blood Stem Cells
      • 4.3.1.4 Peripheral Vascular Disease and Cord Blood Stem Cells
    • 4.3.2 Growth of Public and Private Cord Blood Banks
      • 4.3.2.1 Public Cord Blood (CB) Banks
      • 4.3.2.2 Private Cord Blood Banks
      • 4.3.2.3 The Collection Process of Cord Blood Cells
  • 4.4 Cell Culture Products
    • 4.4.1 In Vitro Test Kits
    • 4.4.2 Suppliers of Cells and Tissues
    • 4.4.3 Suppliers of Culture Media and Cell Reagents
    • 4.4.4 Equipments for Stem Cell Research
    • 4.4.5 Computer Software for Stem Cell Research
  • 4.5 Cell Therapy Market
    • 4.5.1 The Size of the Cell Therapy Industry
    • 4.5.2 The Age, Size and Location of Firms
    • 4.5.3 Firm Technology and Disease Focus
    • 4.5.4 Cell Therapy Products and Companies
    • 4.5.5 Products on the Market
      • 4.5.5.1 First Generation (Non-Stem Cell Based) Primary Products
      • 4.5.5.2 Second Generation (Stem Cell Based) Primary Products
      • 4.5.5.3 Secondary Products
      • 4.5.5.4 Products in Development
      • 4.5.5.5 The Disease Targets of Trials
      • 4.5.5.6 Stem Cell Industry Pipeline
  • 4.6 Industry Collaboration in Stem Cell Space
  • 4.7 Increasing Commercial Success in Stem Cell Industry
  • 4.8 Transition from Tissue Engineering to Regenerative Medicine
  • 4.9 Challenges to Commercial Development of Cell Therapies
    • 4.9.1 Problems of Commercial Viability and Sustainability
    • 4.9.2 Poor Sales and Limited Prospects for Some Forms of Cell Therapy
    • 4.9.3 Lack of Investment from Large Companies
    • 4.9.4 Lack of Clinical Demand and Uptake
  • 4.10 Partnership of Stem Cell Companies with Large Pharmaceutical Companies
    • 4.10.1 Strategic Approaches for Cell-based Companies
    • 4.10.2 The Need for Support from Large Pharmaceuticals

5. Strategic Roadmap to Cell Therapy Industry

  • 5.1 Scope of this Chapter
  • 5.2 Options for the Commercial Manufacturing of Stem Cell Products
  • 5.3 Regulatory Requirements for a Cell Therapy Industry
  • 5.4 In-House Manufacturing of Cell Therapy Products
  • 5.5 Contract Manufacturing
  • 5.6 Effective Clinical Delivery Plan for Cell Therapies
  • 5.7 Business Models in Stem Cell Therapy Sector
  • 5.8 Current Models for Autologous Cell Therapies
  • 5.9 Current Models for Allogeneic Cell Therapies
  • 5.10 Value Chain Considerations and Developmental Path
  • 5.11 Stem Cells: From the Laboratory to the Market
  • 5.11.1 Value Analysis
  • 5.11.2 Clinical Study Development
  • 5.11.3 Product Commercialization
  • 5.11.4 Importance of Specialty Society Support
  • 5.11.5 Payor Coverage

6. Funding for Regenerative Medicine Research

  • 6.1 Scope of this Chapter
  • 6.2 The Intense Competitive Pressure for Funding
  • 6.3 History of Stem Cell Research, Tissue-Engineering and Regenerative Medicine
  • 6.4 The Story of Federal Funding of Stem Cell Research
    • 6.4.1 Policy Changes
    • 6.4.2 Types of Research Ineligible for NIH Funding
    • 6.4.3 NIH Guidelines Addressing the Projected Growth of Stem Cell-Related Clinical Trials
    • 6.4.4 CIRM Funding for Stem Cell Research and Regenerative Medicine
  • 6.5 The Strong Financial Case for Stem Cell Research and Regenerative Medicine
  • 6.5.1 Regenerative Medicine Cost vs. Existing Treatments

7. Current Stem Cell Research

  • 7.1 Scope of this Chapter
  • 7.2 Stem Cell Policies in North America
  • 7.3 Stem Cell Policies in South America
  • 7.4 Stem Cell Policies in Europe
  • 7.5 Stem Cell Policies in Asia/Oceania
  • 7.6 California Institute for Regenerative Medicine (CIRM)
    • 7.6.1 CIRM Collaborative Funding
    • 7.6.2 CIRM' s Funding for Clinical Applications
    • 7.6.3 Early Translational Awards
    • 7.6.4 Disease Team Awards
  • 7.7 Stem Cell Research Programs in Connecticut Department of Public Health
    • 7.7.1 Types of Awards by Connecticut Stem Cell Research Program, 2010
      • 7.7.1.1 Seed Grant Awards
      • 7.7.1.2 Established Investigator Awards
      • 7.7.1.3 Group Project Awards
      • 7.7.1.4 Core Facilities Awards
  • 7.8 Maryland Technology Development Corporation (TEDCO)
    • 7.8.1 TEDCO' s Programs: Funding Opportunities
      • 7.8.1.1 Fort Detrick Technology Transfer Initiative (FDTTI)
      • 7.8.1.2 J&J Investment Fund
      • 7.8.1.3 NAVAIR Technology Insertion (NAVTI) Program
      • 7.8.1.4 The TechStart Program
      • 7.8.1.5 University Technology Development Fund (UTDF)
      • 7.8.1.6 Working Capital Loan Fund
  • 7.9 Maryland Technology Transfer and Commercialization Fund (MTTCF)
    • 7.9.1 Maryland Stem Cell Research Fund
  • 7.10 The New Jersey Commission on Science and Technology (NJCST)
    • 7.10.1 Stem Cell Research in New Jersey
    • 7.10.2 Stem Cell Research Grant Program
  • 7.11 New York State Stem Cell Science (NYSTEM)
    • 7.11.1 Investigator Initiated Research Projects and Innovative (IIRP), Developmental or Exploratory Activities (IDEA) in Stem Cell Research
    • 7.11.2 Targeted RFA for Investigation of iPS and Other Derivation Approaches
    • 7.11.3 Shared Facilities/Resources and Equipment/Instrumentation for Stem Cell Research
    • 7.11.4 Consortia Planning Awards
    • 7.11.5 Institutional Development
    • 7.11.6 Center for Stem Cell and Regenerative Medicine
    • 7.11.7 Funding

8. Company Profiles

  • 8.1 Aastrom Biosciences, Inc.
    • 8.1.1 Aastrom' s TRC Technology
    • 8.1.2 Aastrom' s Patents
    • 8.1.3 Aastrom' s Clinical Development Programs
  • 8.2 Advanced Cell Technology, Inc.
    • 8.2.1 ACT' s Human ES Cell Technologies
    • 8.2.2 ACT' s Cellular Reprogramming
    • 8.2.3 ACT' s Stem Cell Differentiation
    • 8.2.4 ACT' s Adult Stem Cell Program
    • 8.2.5 ACT' s Intellectual Property
  • 8.3 Aldagen, Inc.
  • 8.4 Asterand plc
    • 8.4.1 Asterand' s Models and Methods to Improve Drug Discovery
    • 8.4.2 Asterand' s Product Offerings
      • 8.4.2.1 Asterand' s Frozen and Fixed Tissues
      • 8.4.2.2 Asterand Cell Lines
  • 8.5 Alseres Pharmaceuticals, Inc.
    • 8.5.1 Alseres™ Product Pipeline
      • 8.5.1.1 Cethrin®, a Rho Inhibitor
      • 8.5.1.2 Inosine
      • 8.5.1.3 Oncomodulin and ALSE-100
      • 8.5.1.4 Altropane® - PD
    • 8.5.2 Alseres™ Science and Technology
      • 8.5.2.1 Nerve Repair Pathways
      • 8.5.2.2 The Pro-Regenerative Pathway
      • 8.5.2.3 The Anti-Regenerative Pathway
      • 8.5.2.4 Molecular Imaging
  • 8.6 Amgen, Inc.
    • 8.6.1 Amgen' s Clinical Developments
      • 8.6.1.1 Amgen' s Clinical Developments in Osteoporosis
      • 8.6.1.2 Amgen' s Clinical Developments in Oncology
    • 8.6.2 Amgen' s Select Product Candidates
      • 8.6.2.1 Amgen' s New Product Candidates
  • 8.7 Amorcyte, Inc.
    • 8.7.1 Amorcyte' s Technology
      • 8.7.1.1 AMR-001: A Cell Therapy for Acute Myocardial Infarction
  • 8.8 Angioblast Systems, Inc.
    • 8.8.1 Angioblast' s Technology
      • 8.8.1.1 Angioblast' s Allogenic Adult Stem Cells
      • 8.8.1.2 Angioblast' s Protein Therapeutics
      • 8.8.1.3 Angioblast' s Gene Silencing
  • 8.9 Athersys, Inc.
    • 8.9.1 Athersys™ Current Programs
    • 8.9.2 Athersys™ Regenerative Medicine Programs
      • 8.9.2.1 Multistem for Heart Attack
      • 8.9.2.2 HSC Transplant Support in Hematologic Malignancy
      • 8.9.2.3 Stroke
  • 8.10 BeFutur Biotechnologies
    • 8.10.1 BeFutur' s Serum Free Technology
    • 8.10.2 BeFutur' s Stem Cells
  • 8.11 BD Biosciences
  • 8.12 BioE, Inc.
    • 8.12.1 BioE' s Cell Technologies
      • 8.12.1.1 Application of BioE's Multi-Lineage Progenitor Cell
      • 8.12.1.2 Application of the MLPC in Regenerative Medicine
      • 8.12.1.3 Application of PrepaCyte for Cord Blood
    • 8.12.2 BioE' s Products
      • 8.12.2.1 Multi-Lineage Progenitor Cell (MLPC®)
      • 8.12.2.2 PrepaCyte®-CB
      • 8.12.2.3 PrepaCyte®-WBC
      • 8.12.2.4 ActiCyte®
      • 8.12.2.5 VitaLyse®
  • 8.13 Bioheart, Inc.
    • 8.13.1 Bioheart' s Product Candidates
      • 8.13.1.1 MyoCell®
      • 8.13.1.2 MyoCell SDF-1
      • 8.13.1.3 The TGI 1200 Cell Isolation system
      • 8.13.1.4 Bioheart 3370®
      • 8.13.1.5 MyoCath
  • 8.14 BioMimetic Therapeutics, Inc.
    • 8.14.1 BioMimetic' s Products
      • 8.14.1.1 Augment™ Bone Graft
      • 8.14.1.2 Augment™ Injectable Bone Graft
  • 8.15 Biosafe Group SA
    • 8.15.1 Biosafe' s Sepax System
    • 8.15.2 Coolmix
    • 8.15.3 SepaxNet
  • 8.16 Brainstorm Cell Therapeutics, Inc.
    • 8.16.1 BrainStorm Technology-nurOwn™
  • 8.17 Cardio3 BioSciences
    • 8.17.1 C-Cure™
    • 8.17.2 Dopamine Transporter (DAT)
  • 8.18 CaridianBCT
    • 8.18.1 Caridian' s Products
      • 8.18.1.1 Trima Accel® Collection System
      • 8.18.1.2 Spectra Optia® Apheresis System
      • 8.18.1.3 COBE® Spectra Apheresis System
      • 8.18.1.4 Elutra® Cell Separation System
      • 8.18.1.5 Atreus® Whole Blood Processing System
      • 8.18.1.6 OrbiSac® System
      • 8.18.1.7 COBE® 2991 Cell Processor
  • 8.19 Cellartis AG
    • 8.19.1 Cellartis™ Products
      • 8.19.1.1 Cardiomyocyte Monolayers
      • 8.19.1.2 Cardiomyocyte Clusters
      • 8.19.1.3 Hepatocyte-like Cells
      • 8.19.1.4 Mesenchymal Progenitors
      • 8.19.1.5 The hES Cell Lines
      • 8.19.1.6 Monoclonal Antibodies
      • 8.19.1.7 VitroHES™
      • 8.19.1.8 Stem Culture Tools
  • 8.20 Cellerant Therapeutics, Inc.
    • 8.20.1 Cellerant' s Pipeline
      • 8.20.1.1 CLT-008
  • 8.21 CellCyte Genetics Corporation
    • 8.21.1 CellCyte' s Product Candidates
    • 8.21.2 CellCyte' s Therapeutic Pipeline
      • 8.21.2.1 Heart Repair
      • 8.21.2.2 Cells for Use in the Liver
      • 8.21.2.3 Delivery of Stem Cells to the Bone Marrow
      • 8.21.2.4 Oncology-Adenocarcinoma Tumor Detection
    • 8.21.3 CellCyte' s Device Division
      • 8.21.3.1 Cell Expansion
      • 8.21.3.2 Stem Cell Purification
  • 8.22 Cellerix
    • 8.22.1 Cellerix' s Products
      • 8.22.1.1 Ontaril®
      • 8.22.1.2 Cx501
  • 8.23 CellSeed, Inc.
    • 8.23.1 Regenerative Cornea Product from CellSeed
    • 8.23.2 Regenerative Living Cardiac Patch
  • 8.24 Cellular Dynamics International, Inc. (CDI)
    • 8.24.1 Induced Pluripotent Stem (iPS) Cell Technology
    • 8.24.2 Cardiomyocytes
    • 8.24.3 Mastocytes
  • 8.25 CellTran Ltd.
    • 8.25.1 Myskin™
    • 8.25.2 Lyphoderm
    • 8.25.3 Products in Development
      • 8.25.3.1 Vitiligo Treatment
      • 8.25.3.2 Corneal Epithelial Treatment
      • 8.25.3.3 Cell Migration Dressing
  • 8.26 Cerco Medical
    • 8.26.1 Cerco' s Concept
  • 8.27 Cellular Engineering Technologies, Inc.
    • 8.27.1 CET' s Human Amniotic Epithelial Stem Cells
    • 8.27.2 CET' s Cryopreservation Media
    • 8.27.3 CET' s Adipogenic Differentiation Media
    • 8.27.4 CET' s Cardiomyocyte Differentiation Media
    • 8.27.5 CET' s Chondrogenic Differentiation Media
    • 8.27.6 CET' s Neural Differentiation Media
    • 8.27.7 CET' s Osteogenic Differentiation Media
    • 8.27.8 CET' s Amniotic Epithelial Stem Cell Expansion Media
    • 8.27.9 CET' s Cord Blood Multipotent Unrestricted Somatic Stem Cell Expansion Media
    • 8.27.10 CET' s Mesenchymal Stem Cell Expansion Media
    • 8.27.11 CET' s Human Immunological Cells
    • 8.27.12 CET' s Human Foreskin Fibroblast Cells
    • 8.27.13 CET' s Human Umbilical Vein Endothelial Cell Expansion Media
    • 8.27.14 CET' s Cryopreservation Media
    • 8.27.15 CET' s Bioelectrode Cell-based Assays
    • 8.27.16 CET' s Hepatic Drug Screening
    • 8.27.17 CET' s Neural Drug Screening
    • 8.27.18 CET' s Contract Research Services
  • 8.28 Cord Blood America, Inc.
  • 8.29 CorMatrix® Cardiovascular, Inc.
    • 8.29.1 ECM Technology™
  • 8.30 Cryo-Cell International, Inc.
  • 8.31 Cytori Therapeutics, Inc.
    • 8.31.1 Market for Clinical-Grade Cells
    • 8.31.2 StemSource® and Cell Banking
    • 8.31.3 Celution® System Pipeline
      • 8.31.3.1 Cardiovascular Disease
  • 8.32 CryoLife, Inc.
    • 8.32.1 CryoLife' s Services and Products
      • 8.32.1.1 Tissue Preservation Services
      • 8.32.1.2 Human Cardiac Tissue
      • 8.32.1.3 Human Vascular Tissue
      • 8.32.1.4 Human Orthopedic Tissue
      • 8.32.1.5 ProPatch Soft Tissue Repair Matrix
  • 8.33 Epistem PLC
    • 8.33.1 Xenografting
    • 8.33.2 Cancer Stem Cell Assays
    • 8.33.3 Angiogenesis Models
    • 8.33.4 Colon Cancer Models
    • 8.33.5 Oncology Biomarker Models
    • 8.33.6 In Vitro Cytotoxicity Testing
    • 8.33.7 Target Validation-Oncology
    • 8.33.8 Inflammatory Bowel Disease
    • 8.33.9 Dermatology
    • 8.33.10 Histology and Molecular Services
    • 8.33.11 Epistem' s Biomarkers
    • 8.33.12 Epistem' s New Therapies
  • 8.34 ES Cell International Pvt, Ltd.
    • 8.34.1 ESI' s Technology
    • 8.34.2 ESI' s Intellectual Property
  • 8.35 Forticell Bioscience, Inc.
  • 8.36 OrCel®
    • 8.36.1 Technology
  • 8.37 Gamida Cell
    • 8.37.1 Gamida' s Technology
  • 8.38 GenVec, Inc.
  • 8.39 Geron Corporation
    • 8.39.1 Geron and Human Embryonic Stem Cell Therapies
    • 8.39.2 Geron' s Oligodendrocyte Progenitor Cells for Spinal Cord Injury (GRNOPC1)
    • 8.39.3 Geron' s Cardiomyocytes for Heart Disease (GRNCM1)
    • 8.39.4 Geron' s Islet Cells for Diabetes (GRNIC1)
    • 8.39.5 Geron' s Osteoblasts for Osteoporosis and Non-Union Bone Fractures
    • 8.39.6 Geron' s Chondrocytes for Osteoarthritis
    • 8.39.7 Geron' s Dendritic Cells for Cancer Immunotherapy and to enable Therapeutic Graft Acceptance
    • 8.39.8 Geron' s Immortalized Cells for Research
    • 8.39.9 Geron' s hESC-derived Cells for Drug Screening and Toxicology
  • 8.40 Glycosan Biosystems, Inc.
    • 8.40.1 Extracel™ Hydrogel Kit
    • 8.40.2 Extracel-X™ Hydrogel Kit
    • 8.40.3 Extracel-HP™ Hydrogel Kit
    • 8.40.4 Extracel-SS™ Hydrogel Kit
    • 8.40.5 HyStem™ Hydrogel Kit
    • 8.40.6 HyStem-C™ Hydrogel Kit
    • 8.40.7 HyStem-HP™ Hydrogel Kit
    • 8.40.8 HyStem-CSS™ Hydrogel Kit
    • 8.40.9 PEGDA
    • 8.40.10 PEGTA
    • 8.40.11 PEGSSDA™ (PEGSSDA)
  • 8.41 Humacyte, Inc.
    • 8.41.1 Humacyte' s Technologies
      • 8.41.1.1 Vascular Products
      • 8.41.1.2 Injectable Products
      • 8.41.1.3 Human Embryonic Stem Cell Therapies
  • 8.42 Intercytex Group plc
    • 8.42.1 Intercytex' s Pipeline
      • 8.42.1.1 VAVELTA® - Skin Repair and Rejuvenation
      • 8.42.1.2 SHEF-1 - Stem Cell Line
      • 8.42.1.3 ICX-SKN-Skin Graft Replacement for Burns and Acute Wounds
      • 8.42.1.4 ICX-TRC - Hair Regeneration
      • 8.42.1.5 Cyzact®-Chronic Wound Repair
  • 8.43 Integra LifeSciences Holding, Corp.
    • 8.43.1 Integra' s Duraplasty Products
    • 8.43.2 Integra' s Collagen for Spine
    • 8.43.3 Integra' s Dermal Regeneration and Engineered Wound Dressings
    • 8.43.4 Integra' s Nerve and Tendon Products
    • 8.43.5 Human Cells, Tissues and Cellular and Tissue-Based Products from Integra
  • 8.44 International Stem Cell Corporation
    • 8.44.1 ISCO' s Technology
      • 8.44.1.1 Somatic Cell Nuclear Transfer
      • 8.44.1.2 Parthenogenesis
      • 8.44.1.3 ISCO' s Therapeutic Focus
      • 8.44.1.4 Retinal Degeneration
      • 8.44.1.5 Diabetes Therapies
      • 8.44.1.6 Liver Therapies
    • 8.44.2 ISCO' s Products
  • 8.45 Japan Tissue Engineering Co., Ltd.
    • 8.45.1 Cultured Epidermis
    • 8.45.2 Cultured Cartilage
    • 8.45.3 Cultured Corneal Epithelium
  • 8.46 LifebankUSA
    • 8.46.1 Cord Blood Banking
  • 8.47 Life Technologies Corporation
    • 8.47.1 Life Technologies™ Customers
      • 8.47.1.1 Life Science Researchers
      • 8.47.1.2 Commercial Producers of Biopharmaceutical and Other High-Valued Proteins
      • 8.47.1.3 Applied Markets
    • 8.47.2 Life Technologies™ Products
  • 8.48 Lonza
    • 8.48.1 Lonza' s Products and Applications
  • 8.49 MedCell Bioscience, Ltd.
    • 8.49.1 MedCell' s MS-ten Technology
  • 8.50 Medistem, Inc.
    • 8.50.1 Method for Expansion of Stem Cells
    • 8.50.2 Compositions of Placentally-derived Stem Cells for the Treatment of Cancer
    • 8.50.3 Transcatheter Tumor Immunoembolization
    • 8.50.4 Stem Cell Therapy for Cardiac Valvular Dysfunction
    • 8.50.5 Treatment of Erectile Dysfunction by Stem Cell Therapy
    • 8.50.6 Allogeneic Stem Cell Transplants in Non-Conditioned Recipients
    • 8.50.7 Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune Modulation
    • 8.50.8 Cellular Therapy for Lower Back Pain
    • 8.50.9 Compositions and Methods of Stem Cell Therapy for Autism
    • 8.50.10 Stem Cell Therapy for Weight Loss
    • 8.50.11 Menstrual Blood Cellular Populations, Isolation, and Use Thereof
    • 8.50.12 Endometrial Derived Reparative/Regenerative Cells
    • 8.50.13 Treatment of Insulin Resistance and Diabetes
    • 8.50.14 Combination Treatment of Cardiovascular Disease
    • 8.50.15 Stem Cell Therapy for Autism
    • 8.50.16 Endometrial Regenerative Stem Cell Line
    • 8.50.17 Medistem' s Angiostem Platform
  • 8.51 Mesoblast Limited
    • 8.51.1 Mesoblast' s Technologies
    • 8.51.2 Mesoblast' s Applications in Bone Repair
      • 8.51.2.1 Cartilage Regeneration
      • 8.51.2.2 Disc Regrowth
    • 8.51.3 Mesoblast' s Application in Heart Attack
      • 8.51.3.1 Congestive Heart Failure
      • 8.51.3.2 Peripheral Arterial Disease
    • 8.51.4 Mesoblast' s Application in Wound Ulcers
    • 8.51.5 Mesoblast' s Process and Product Development
      • 8.51.5.1 GMP Process Development
      • 8.51.5.2 Proof of Principle Models
  • 8.52 Millipore Corporation
    • 8.52.1 Millipore' s Drug Discovery and Development Services
    • 8.52.2 Millipore' s Research and Development
  • 8.53 Miltenyi Biotec
  • 8.53.1 Miltenyi Biotec' s MACS® Technology
    • 8.53.2 MACS® Cell Analysis
    • 8.53.3 MACS® Cell Culture product line
  • 8.54 Neostem, Inc.
    • 8.54.1 NeoStem' s Services
  • 8.55 NeuralStem, Inc.
    • 8.55.1 NeuralStem' s Focus on Regenerative Medicine
    • 8.55.2 The Potential of NeuralStem' s Tissue-Derived Stem Cell-based Therapy
    • 8.55.3 Potential Markets
    • 8.55.4 NeuralStem' s Technology
    • 8.55.5 NeuralStem' s Research Programs
  • 8.56 NeuroGeneration
    • 8.56.1 NeuroGeneration' s Stem Cell Therapy
  • 8.57 Novocell, Inc.
    • 8.57.1 Novocell and Stem Cell Engineering
    • 8.57.2 Novocell and Cell Encapsulation
    • 8.57.3 Novocell' s Clinical Trials
  • 8.58 Opexa Therapeutics, Inc.
    • 8.58.1 Opexa' s Products
      • 8.58.1.1 Tovaxin®
      • 8.58.1.2 Current MS Treatments
  • 8.59 Organogenesis, Inc.
    • 8.59.1 Products from Organogenesis
      • 8.59.1.1 Apligraft®
      • 8.59.1.2 VCT01™
      • 8.59.1.3 CelTx™ for Oral Soft Tissue Regeneration
    • 8.59.2 Bio-surgery
      • 8.59.2.1 FortaFlex®
    • 8.59.3 Licensing Opportunities
      • 8.59.3.1 FortaFlex® Collagen Biomaterial Technology
  • 8.60 Orthovita, Inc.
    • 8.60.1 Orthovita' s Products and Product Candidates
      • 8.60.1.1 Orthovita' s Bone Defect Grafting Products
      • 8.60.1.2 Orthovita' s Spinal Fusion and Grafting Products
      • 8.60.1.3 Orthovita' s Trauma Products
      • 8.60.1.4 Orthovita' s Dental, Periodontal, Oral and Cranio-Maxillofacial Products
  • 8.61 Osiris Therapeutics, Inc.
  • 8.62 Pervasis Therapeutics, Inc.
    • 8.62.1 Vascugel®
    • 8.62.2 PVS-10200 - Minimally Invasive
  • 8.63 Pleuron Corp.
    • 8.63.1 Plureon' s Technology
  • 8.64 Pluristem Therapeutics, Inc.
    • 8.64.1 Pluristem's PluriX™ 3D Bioreactor
    • 8.64.2 Pluristem's PLacental eXpanded (PLX) Cells
    • 8.64.3 PLX-PAD for Peripheral Artery Disease
    • 8.64.4 PLX-IBD for Inflammatory Bowel Disease (Crohn' s Disease and Ulcerative Colitis)
    • 8.64.5 PLX-MS for Multiple Sclerosis
    • 8.64.6 PLX-STROKE for Ischemic Stroke
  • 8.65 Reinnervate LLC
    • 8.65.1 Reinnervate' s Technology
    • 8.65.2 Reinnervate' s Culture Apparatus for Three Dimensional Cell Growth
    • 8.65.3 Production of Synthetic Retinoids to Control Cell Differentiation
  • 8.66 Regenocyte Therapeutic
    • 8.66.1 Regenocyte' s Adult Stem Cell Therapy
  • 8.67 ReNeuron Group Plc
    • 8.67.1 ReNeuron' s Platform Technologies
    • 8.67.2 ReNeuron' s Cell Therapy Programs
    • 8.67.3 ReNcell® Products
  • 8.68 Saneron Therapeutics, Inc.
    • 8.68.1 Saneron' s U-CORD-CELL™ Program
    • 8.68.2 Saneron' s SERT-CELL™ Program
  • 8.69 Scikon Innovation, Inc.
    • 8.69.1 Scikon' s Human Cell Products
  • 8.70 Stem Cells, Inc.
    • 8.70.1 StemCell' s Specialty Cell Culture Products
    • 8.70.2 StemCell' s Patents
  • 8.71 StemCell Technologies, Inc.
    • 8.71.1 SCT' s Products
    • 8.71.2 Hematopoietic Stem Cell Research
    • 8.71.3 SCT' s Mesenchymal Stem Cell Products for Human Cells
    • 8.71.4 SCT' s Products for Neural Stem Cells Research
    • 8.71.5 Stem Cell Innovations (SCI)
    • 8.71.6 SCI' s Research and Development
    • 8.71.7 SCI' s Services
      • 8.71.7.1 PluriCells™ and Derivatives
      • 8.71.7.2 ACTIVTox®
      • 8.71.7.3 PREDICTIVTox®
      • 8.71.7.4 Endogenous Protein Production
  • 8.72 Stem Cell Sciences KK
    • 8.72.1 Cell-Based Therapy
    • 8.72.2 SCS KK' s Product/Service
      • 8.72.2.1 CultiCell Medium for Embryonic Stem Cells
  • 8.72.3 Contract/Sponsored Research on ES-Derived Functional Cells
  • 8.73 Stem Cell Therapy International, Inc.
    • 8.73.1 Biological Preparations
    • 8.73.2 Treatment of Patients with Diabetes
    • 8.73.3 Treatment of Patients with Diabetic Retinopathy
    • 8.73.4 Atherosclerosis Coronary Heart Disease and Cerebral Ischemia
    • 8.73.5 Liver Cirrhosis
    • 8.73.6 Non-Specific Ulcerative Colitis (Crohn' s Disease)
    • 8.73.7 Immunomodulation before Capital Surgical Operations Wound Dystrophy
    • 8.73.8 Acute Surgical Complications
    • 8.73.9 Peritoneal Commissures of the Abdominal Cavity
    • 8.73.10 Immunodeficient States in Children
    • 8.73.11 Sickle-Cell Anemia Therapy
    • 8.73.12 Complex Therapy of Down' s Disease
    • 8.73.13 Complex Therapy of Cosmetic Problems
    • 8.73.14 Diseases and Disorders of Nervous System
  • 8.74 Stempeutics Research Private Limited
    • 8.74.1 Research: Mesenchymal Stem Cells Derived from Wharton' s Jelly
    • 8.74.2 Research: Mesenchymal Stem Cells Derived from Adipose Tissue
    • 8.74.3 Research: Mesenchymal Stem Cells Derived from Dental Pulp
    • 8.74.4 Research: Large Scale Upscaling of Mesenchymal Stem Cells
    • 8.74.5 Research: Human Embryonic Stem Cells
    • 8.74.6 Stempeutics™ Clinical Trials
      • 8.74.6.1 Acute Myocardial Infarction (AMI)
      • 8.74.6.2 Critical Limb Ischemia (CLI)
      • 8.74.6.3 Chronic Obstructive Pulmonary Disease
      • 8.74.6.4 Liver Cirrhosis
      • 8.74.6.5 Osteoarthritis
      • 8.74.6.6 Diabetes Mellitus™ Type II
      • 8.74.6.7 Cerebral Stroke (This Trial is being Conducted in Malaysia)
  • 8.75 Tengion, Inc.
    • 8.75.1 Tengion' s Technology
    • 8.75.2 Tengion' s Pipeline
  • 8.76 TheraVitae
    • 8.76.1 TheraVitae' s Stem Cell Technology
    • 8.76.2 TheraVitae' s Products
      • 8.76.2.1 VesCell™ for Heart Disease
      • 8.76.2.2 VesCell™ for Peripheral Artery Disease (PAD)
      • 8.76.2.3 Future Products
  • 8.77 VistaGen Therapeutics, Inc.
    • 8.77.1 VistaGen' s Embryonic Stem Cell Technologies
    • 8.77.2 Tools for Drug Discovery and Regenerative Medicine
    • 8.77.3 New Generation Drug Screening Assays for Neurological Drugs
    • 8.77.4 New Generation Drug Screening Assays for Metabolic Diseases
    • 8.77.5 Toxicity Screening
    • 8.78 ZenBio, Inc.
  • 8.78.1 ZenBio' s Culture Media

Appendix 1: Clinical Trials in Stem Cell Space

Appendix 2: Stem Cell Glossary

Appendix 3: Consultants in Cell Therapy Sector

INDEX OF FIGURES

  • Figure 2.1: Derivation of Human Embryonic Stem Cells (hESC)
  • Figure 2.2: Differentiation of Embryonic Stem Cells into Specialized Cell Types
  • Figure 2.3: Hematopoietic and Stromal Cell Differentiation
  • Figure 2.4: Somatic Cell Nuclear Transfer (SCNT)
  • Figure 3.1: Percent Population of Patient Pool with Unmet Clinical Need
  • Figure 3.2: Implantation of a Hydrogel at the Site of an Injured Tissue
  • Figure 3.3: Implantation of CS-PEG Hydrogel
  • Figure 3.4: Implantation of CMP-PEG Scaffold
  • Figure 4.1: Market for the Three Major Segments of Stem Cell Market, 2008-2012
  • Figure 4.2: Market for Cell Therapy Products in the U.S., 2009-2018
  • Figure 4.3: Utilization of Stem Cell Types in Stem Cell Market Place, 2008
  • Figure 4.4: Potential Uses of Human Embryonic Stem Cells (hESCs)
  • Figure 4.5: Global Market for Cord Blood Stem Cells, 2010-2015
  • Figure 4.6: Worldwide Growth of Public Cord Blood Banks, 2005-2009
  • Figure 4.7: Worldwide Growth of Private Cord Blood Banks, 2005-2009
  • Figure 4.8: Standard Procedure for Cord Blood Processing
  • Figure 4.9: Cell Culture Products by Market Segment
  • Figure 4.10: Global Market for Cell and Tissue Analysis Products, 2008-2014
  • Figure 4.11: Growth in Size of Cell Therapy Industry, 2000-2008
  • Figure 4.12: Percent Break-Up of Cell Therapy Companies by Product Type, 2008
  • Figure 4.13: Location of Primary Tissue Engineering Companies (%) by Geography, 2008/2009
  • Figure 4.14: Breakdown (%) of Primary Cell Therapy Products on Market by Geography, 2008/2009
  • Figure 4.15: Geographical Distribution of Clinical Trials, 2008/2009
  • Figure 5.1: Value Chain of Mesenchymal Stem Cell Therapeutics
  • Figure 5.2: Use of Coverage and Reimbursement Knowledge in the Product Life Cycle
  • Figure 6.1: Increase in Worldwide Funding for Cell Therapy Products, 2008-2018
  • Figure 7.1: CIRM' s Grant Awards (%) by Category, 2009
  • Figure 7.2: CIRM' s Funding (%) by Disease Application, 2009
  • Figure 7.3: CIRM' s Funding (%) by Disease Category, 2009
  • Figure 8.1: Cardio3 Biosciences™ Investors, 2008
  • Figure 8.2: Relative Success of Cord Blood Stem Cells from Autogenic Donor
  • Figure A1.1: Clinical Studies on Cell Therapy related Products by Country, 2010

INDEX OF TABLES

  • Table 2.1: Different Types of Stem Cells and Their Properties
  • Table 2.2: Adult Stem Cell (ASC) Differentiation Properties
  • Table 2.3: HSC Sources and Their Properties
  • Table 3.1: Stem Cell Therapeutics for Orthopedic Disease in Development
  • Table 3.2: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
  • Table 3.3: Stem Cell Therapeutics for Type I Diabetes in Development
  • Table 3.4: Stem Cell Therapeutics for Neurological Disease in Development
  • Table 3.5: Stem Cell-based Therapeutics for Vascular Diseases in Development
  • Table 3.6: Stem Cell Therapeutics for Hematological Diseases in Development
  • Table 3.7: Products in Development: Target Indications, 2008
  • Table 3.8: Top Ten Regenerative Medicine Products, 2008
  • Table 3.9: Wound Healing Products
  • Table 3.10: Autologous Tissue-Engineering Products from BioTissue Technologies AG
  • Table 3.11: co.don®s Product Portfolio
  • Table 4.1: Entities Developing hSCs
  • Table 4.2: Biotech and Pharmaceutical Companies Investing in hESC Research
  • Table 4.3: Selected Cord Blood Banks Worldwide
  • Table 4.4: Selected Cord Blood Banks in the U.S.
  • Table 4.5: Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space
  • Table 4.6: Some Selected Suppliers of In Vitro Test Kits and their Products
  • Table 4.7: Suppliers of Cells and Tissues
  • Table 4.8: Suppliers of Media and Cell Reagents
  • Table 4.9: Providers of Equipments for Stem Cell Research
  • Table 4.10: Providers of Computer Software for Stem Cell Research
  • Table 4.11: Geographical Distribution of Stem Cell-Related Tissue Engineering Companies, 2008
  • Table 4.12: Breakdown of Cell Therapy Firms by Country, 2008/2009
  • Table 4.13: Cell Therapy Products on the Market by Type and Application Area
  • Table 4.14: Data on Sales and Application for Skin and Cartilage Products, 2006-2008
  • Table 4.15: Reagent Sales by Selected Stem Cell Companies, 2008
  • Table 4.16: Sales of Secondary Products, 2007
  • Table 4.17: Disease Focus of Clinical Trials, 2008/2009
  • Table 4.18: Stem Cell Products in Phase II/III and Phase III Trials, 2008/2009
  • Table 4.19: Licensing Activity in Pharmaceutical and Cell Therapy Industries
  • Table 4.20: Investment Activity in Cell Therapy Sector
  • Table 4.21: Novel Partnership by Large Pharmaceuticals with Universities
  • Table 4.22: Cell Therapy Companies with Greater Than $10 Million by Market Cap, 2008
  • Table 5.1: Elements of a Manufacturing Facility
  • Table 5.2: Cell Therapy CMO Qualification Audit: Points to Investigate
  • Table 5.3: Areas for Coverage and Reimbursement Competency and Planning
  • Table 6.1: Cell-Based Regenerative Medicine Companies
  • Table 6.2: NIH Funding for Regenerative Medicine and Stem Cell Research, 2003-2009
  • Table 6.3: NIH Funding for Various Types of Stem Cell Research, 2004-2009
  • Table 6.4: CIRM Funded Grants To-Date
  • Table 6.5: Economic Costs of Major Illnesses in the U.S. and the Number of Patients
  • Table 6.6: Costs per Quality-Adjusted Life Year for Various Interventions
  • Table 7.1: Stem Cell Policies in North America
  • Table 7.2: Stem Cell Policies in South America
  • Table 7.3: Stem Cell Policies in Europe
  • Table 7.4: Stem Cell Policies in Asia/Oceania
  • Table 7.5: List of Upcoming Request for Applications (RFAs) Showing Commitments from Funding Partners
  • Table 7.6: Recipients of Funds from Connecticut Stem Cell Research Program, 2009
  • Table 7.7: Maryland Stem Cell Research Fund, 2008
  • Table 7.8: NJCST' s Award of Grants for Stem Cell Research, 2008
  • Table 7.9: NYSTEM' s IIRP Awards, 2008
  • Table 8.1: Aastrom' s Patents, 2010
  • Table 8.2: Aastrom' s Product Pipeline, 2010
  • Table 8.3: Patents Owned by Advanced Cell Technologies, Inc., 2009
  • Table 8.4: Asterand' s Frozen and Fixed Tissue Products, 2010
  • Table 8.5: Alseres™ Product Pipeline, 2009
  • Table 8.6: Amgen' s Outstanding Material Patents for Darbepoetin Alfa
  • Table 8.7: Amgen' s Outstanding Material Patents for Epoietin Alfa
  • Table 8.8: Amgen' s Outstanding Material Patents for Pegfilgrastim
  • Table 8.9: Amgen' s Product Candidates
  • Table 8.10: Amgen' s Product Candidates by Phase of Development
  • Table 8.11: Angioblast' s Product Development
  • Table 8.12: BD Biosciences™ Customers and Products
  • Table 8.13: BD Biosciences™ Revenue by Segment, 2008 and 2009
  • Table 8.14: Bioheart' s Patents, 2009
  • Table 8.15: Bioheart' s Pending Patent Applications, 2009
  • Table 8.16: Bioheart' s Clinical Trials, 2009
  • Table 8.17: BioMimetic' s Clinical Data, 2010
  • Table 8.18: Cellerant' s Pipeline
  • Table 8.19: Private Cord Blood Banking vs. Public Donation
  • Table 8.20: Cytori' s Celution® System Family and its Regulatory Status, 2009
  • Table 8.21: ESI' s Patents in Stem Cell Field, 2009
  • Table 8.22: Gamida' s Pipeline, 2009
  • Table 8.23: hESC-derived Product Candidates Being Developed by Geron or Its Collaborators
  • Table 8.24: Intercytex™ Product Pipeline, 2009
  • Table 8.25: LifebankUSA' s Cord Blood Units Released for Transplant Standard Therapies
  • Table 8.26: Medistem' s Patent Applications
  • Table 8.27: Millipore' s Products in Apoptosis and Cell Biology
  • Table 8.28: Millipore' s Products in Biomarkers
  • Table 8.29: Millipore' s Products in Cell Culture and Stem Cell Biology
  • Table 8.30: Millipore' s Products in Cell Signaling and Epigenetics
  • Table 8.31: Millipore' s Drug Discovery and Development Services
  • Table 8.32: Potential Target Markets for Stem Cell Therapies in the U.S.
  • Table 8.33: Issued and Pending Patents Owned by NeuralStem, Inc.
  • Table 8.34: Opexa' s Pipeline, 2009
  • Table 8.35: Orthovita' s Bone Graft Products, 2009
  • Table 8.36: Orthovita' s Bone Marrow Aspiration Tools, 2009
  • Table 8.37: Osiris™ Biologic Drug Candidates, 2010
  • Table 8.38: Pervasive' s Product Pipeline
  • Table 8.39: Scikon' s Media for Cell seeding and Culture, 2010
  • Table 8.40: Current Status of StemCell' s Two Therapeutic Product Development Programs
  • Table 8.41: StemCell' s Specialty Cell Culture Products
  • Table 8.42: StemCell' s U.S. Patents, 2009
  • Table 8.43: Cell Types Separated by SCT' s Four Solutions
  • Table 8.44: Products Offered by SCT for Hematopoietic Stem Cell Research
  • Table 8.45: SCT' s Products for Human Embryonic Stem Cell Research
  • Table 8.46: SCT' s Products for Mesenchymal Stem Cell Research
  • Table 8.47: SCT' s Products for Neural Stem Research
  • Table 8.48: SCT' s Other Products for Stem Cell Related Research
  • Table 8.49: Tengion' s Pipeline
  • Table 8.50: ZenBio' s Products
  • Table A1.1: Stem Cells in Clinical Trials
  • Table A3.1: Consultants in Cell Therapy Sector

Press Release

幹細胞市場的動向

2010年06月21日

Global Information, Inc.已開始銷售總公司設在紐約的市場調查公司Trimark Publications所發行的報告書「Stem Cell Markets (幹細胞市場)」

近幾年藉由對幹細胞生物學的理解，為心血管系疾病、組織/內臟器官損傷、神經系統疾病、筋骨格疾病、造血障礙、糖尿病等許多疾病，帶來新的治療方法之可能性。幹細胞產品基本上分成1)骨髓內具再生能力的造血幹細胞；2)具分化成神經與腦組織能力的神經幹細胞；3)具分化成骨、脂肪、軟骨、胰臟β細胞能力的間葉幹細胞/胰島幹細胞等3種幹細胞。其各自基礎性的幹細胞產品對各種疾病與障礙有益。例如，神經幹細胞被認為對阿爾茨海默與帕金森氏病等神經變性疾病有治療價值。

依據終端用戶用途，現在的幹細胞市場主要可區分為1)創藥•醫藥品開發的毒性篩選；2)自己細胞治療； 3)同種細胞治療等3種。依據該報告，現在的幹細胞治療及幹細胞技術的市場機會完全侷限於對研究機關等的試劑、培養基、細胞、消耗品、服務銷售等框架內。此時點尚未有獲得美國FDA(Food and Drug Administration)認可的正式幹細胞治療。Trimark預測幹細胞基本的治療在今後3-5年內將對市場有影響力。

是該書討論對象的主要話題：

  • 細胞治療市場的現狀
  • 細胞治療的可能性
  • 幹細胞市場現在的主要企業為何
  • 各種幹細胞技術平台的優點
  • 現在可利用的幹細胞技術主要類型
  • 幹細胞領域主要企業導入的主要幹細胞商務策略為何
  • 幹細胞市場顯示最高成長可能性的領域為何
  • 新的幹細胞技術能如何改善對患者的護理
Back to Top